Skip to main content

Table 2 Prognostic factors for overall survival

From: Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma

  Univariate model Multivariate model
Factor HR (95%CI) P value HR (95%CI) P value
Age (61 ≤) 2.2 (0.8–6.7) 0.15 - -
Sex (male) 2.6 (0.7–9.3) 0.14 - -
Stage III, IV 7.6 (1.0–5.8) 0.15 - -
Extranodal site (2 ≤) 1.7 (0.6–4.8) 0.35 - -
LDH (> upper normal limit) 1.8 (0.5–5.8) 0.34 - -
Performance status (2–4) 2.8 (1.0–8.1) 0.05 - -
RDI (CPA+DOX) per 0.1 0.7 (0.6–0.9) 0.02* 0.8 (0.6–1.0) 0.08
IPI (high/high intermediate) 4.7 (1.3–17) 0.02* 3.8 (1.0–14) 0.05
Albumin (3.5 mg/dl ≤) 0.7 (0.4–1.2) 0.20 - -
Prophylactic G-CSF 1.6 (0.5–4.9) 0.44 - -
  1. HR: hazard ratio; CI: confidence interval; RDI: relative dose intensity; CPA: cyclophosphamide; DOX: doxorubicin; G-CSF: granulocyte colony-stimulating factor